Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia 3Hematologic Neoplasms 3Multiple Myeloma 2Melanoma 2Lymphoma, Non-Hodgkin 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Pancreatic Carcinoma 1Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Respiratory Tract Infections 1Respiratory Distress Syndrome 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Lymphoma, Mantle-Cell 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immune-related Adverse Events 1

Interventions

Methotrexate 3olokizumab 2veltuzumab 1upadacitinib 1tocilizumab 1mavrilimumab 1golimumab 1andecaliximab 1Vaccines 1Tumor Necrosis Factor Inhibitors 1TACI receptor-IgG Fc fragment fusion protein 1Saline Solution 1RC-18 1Interleukin 1 Receptor Antagonist Protein 1ISIS104838 1Herpes Zoster Vaccine 1Bortezomib 1Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Arthritis, Rheumatoid × tocilizumab × Clear all
NCT01242488 2024-07-17

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

UCB Pharma

Phase 2 Completed
221 enrolled

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡